Your browser doesn't support javascript.
loading
Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary.
Higgins, Peter D R; Harding, Gale; Leidy, Nancy K; DeBusk, Kendra; Patrick, Donald L; Viswanathan, Hema N; Fitzgerald, Kristina; Donelson, Sarah M; Cyrille, Marcoli; Ortmeier, Brian G; Wilson, Hilary; Revicki, Dennis A; Globe, Gary.
Afiliación
  • Higgins PDR; 1University of Michigan, Ann Arbor, MI USA.
  • Harding G; 6IBD Program University of Michigan, SPC 5682, 1650 West Medical Center Drive, Ann Arbor, MI 48109 USA.
  • Leidy NK; 2Evidera, Bethesda, MD USA.
  • DeBusk K; 2Evidera, Bethesda, MD USA.
  • Patrick DL; 3Genentech Inc., South San Francisco, CA USA.
  • Viswanathan HN; 4University of Washington, Seattle, WA USA.
  • Fitzgerald K; 5Amgen Inc., Thousand Oaks, CA USA.
  • Donelson SM; 7Present address: Allergan Inc., Irvine, CA USA.
  • Cyrille M; 3Genentech Inc., South San Francisco, CA USA.
  • Ortmeier BG; 3Genentech Inc., South San Francisco, CA USA.
  • Wilson H; 5Amgen Inc., Thousand Oaks, CA USA.
  • Revicki DA; 5Amgen Inc., Thousand Oaks, CA USA.
  • Globe G; 2Evidera, Bethesda, MD USA.
J Patient Rep Outcomes ; 2(1): 24, 2017.
Article en En | MEDLINE | ID: mdl-29770803
BACKGROUND: The clinical course of Crohn's disease (CD) and the effect of its treatment are monitored through patient-reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Crohn's Disease Patient-reported Outcomes Signs and Symptoms (CD-PRO/SS) measure was developed to standardize the quantification of gastrointestinal S&S of CD through direct report from patient ratings. METHODS: The CD-PRO/SS was developed based on data from concept elicitation (focus groups, interviews; n = 29), then refined through cognitive interviews of CD patients (n = 20). Measurement properties, including item-level statistics, scaling structure, reliability, and validity, were examined using secondary analyses of baseline and two-week clinical trial data of adults with moderate-to-severe CD (n = 238). RESULTS: Findings from qualitative interviews identified nine S&S items covering bowel and abdominal symptoms. The final CD-PRO/SS daily diary includes two scales: Bowel S&S (three items) and Abdominal Symptoms (three items), each scored separately. Each scale showed evidence of adequate reliability (α = 0.74 and 0.67, respectively); reproducibility (intraclass correlation coefficient > 0.80), and validity, with the last including moderate correlations with the Inflammatory Bowel Disease Questionnaire bowel symptom score and select items (ranging from r = 0.43-0.54). Scores distinguished patients categorized by patient global ratings of disease severity (p < 0.0001). CONCLUSIONS: Results suggest the CD-PRO/SS is a reliable and valid measure of gastrointestinal symptom severity in CD patients. Additional longitudinal data are needed to evaluate the ability of the CD-PRO/SS scores to detect responsiveness and inform the selection of responder definitions.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Qualitative_research Idioma: En Revista: J Patient Rep Outcomes Año: 2017 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Qualitative_research Idioma: En Revista: J Patient Rep Outcomes Año: 2017 Tipo del documento: Article